{
    "nct_id": "NCT05316688",
    "official_title": "Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent",
    "inclusion_criteria": "* Adult subjects age >= 18 years (yr)\n* Subjects must have suspected or confirmed oral cavity dysplasia or cT1-4 squamous cell carcinoma for which surgical excision is deemed clinically indicated by the treating physician. Histology confirmation not required prior to surgery\n* Able to provide written informed consent\n* If of child-bearing potential, agree to the continued use of 2 reliable forms of contraception from study enrollment through 30 days after receiving the study product. Male subjects must agree to use 2 reliable methods of contraception simultaneously for 30 days after receiving the study product if their partner is of child-bearing potential\n* Available for all study visits and able to comply with all study requirements\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected sensitivity to indocyanine green\n* In the opinion of the treating physician, subject has received photosensitizing medication that could interfere or confound study results\n* Any current medications with the potential to generate fluorescence or photochemical reaction\n* Enrolled in any other ongoing study\n* Currently lactating or breastfeeding\n* Positive pregnancy test or planning to become pregnant within 30 days (d) of receiving tozuleristide\n* Any current condition, including psychological and social situations which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data\n* Creatinine clearance < 60 mL/min\n* Aspartate aminotransferase (AST) > 1.5 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) > 1.5 x ULN\n* Bilirubin > 1.5 x ULN",
    "miscellaneous_criteria": ""
}